Bollerslev J, et al. European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE educational program of parathyroid disorders. Eur J Endocrinol. 2022;186(2):R33–63. https://doi.org/10.1530/EJE-21-1044.

Article  CAS  PubMed  Google Scholar 

Khan AA, et al. Management of hypoparathyroidism. J Bone Miner Res. 2022;37(12):2663–77. https://doi.org/10.1002/jbmr.4716.

Article  CAS  PubMed  Google Scholar 

Van Uum S, et al. Initial Assessment and monitoring of patients with chronic hypoparathyroidism: a systematic current practice survey. J Bone Miner Res. 2022;37(12):2630–41. https://doi.org/10.1002/JBMR.4698.

Article  PubMed  Google Scholar 

Mannstadt M et al. “Hypoparathyroidism,” Nat Rev Dis Primers. 2017;3 https://doi.org/10.1038/NRDP.2017.55.

Palermo A, et al. PTH(1–34) for Surgical Hypoparathyroidism: A 2-year prospective, open-label investigation of efficacy and quality of life. J Clin Endocrinol Metab. 2018;103(1):271–80. https://doi.org/10.1210/JC.2017-01555.

Article  PubMed  Google Scholar 

Mannstadt M, et al. Efficacy and safety of recombinant human parathyroid hormone (1–84) in hypoparathyroidism (REPLACE): a double-blind, placebo-controlled, randomised, phase 3 study. Lancet Diabetes Endocrinol. 2013;1(4):275–83. https://doi.org/10.1016/S2213-8587(13)70106-2.

Article  CAS  PubMed  Google Scholar 

Rejnmark L. Treatment of hypoparathyroidism by re-establishing the effects of parathyroid hormone. Endocrinol Metab. 2024;39(2):262–6. https://doi.org/10.3803/ENM.2024.1916.

Article  CAS  Google Scholar 

Clarke BL, et al. Efficacy and Safety of TransCon PTH in Adults with Hypoparathyroidism: 52-Week Results From the Phase 3 PaTHway Trial. J Clin Endocrinol Metab. 2024. https://doi.org/10.1210/CLINEM/DGAE693.

Article  PubMed  Google Scholar 

Rejnmark L, et al. Palopegteriparatide Treatment Improves Renal Function in Adults with Chronic Hypoparathyroidism: 1-Year Results from the Phase 3 PaTHway Trial. Adv Ther. 2024;41(6):2500–18. https://doi.org/10.1007/S12325-024-02843-8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Khan AA, et al. Efficacy and Safety of Parathyroid Hormone Replacement With TransCon PTH in Hypoparathyroidism: 26-Week Results From the Phase 3 PaTHway Trial. J Bone Miner Res. 2023;38(1):14–25. https://doi.org/10.1002/JBMR.4726.

Article  CAS  PubMed  Google Scholar 

Clarke BL, Kay Berg J, Fox J, Cyran JA, Lagast H. “Pharmacokinetics and pharmacodynamics of subcutaneous recombinant parathyroid hormone (1–84) in patients with hypoparathyroidism: an open-label, single-dose, phase I study,” Clin Ther. 2014;36(5):722–736 https://doi.org/10.1016/J.CLINTHERA.2014.04.001.

Sikjaer T, Amstrup AK, Rolighed L, Kjaer SG, Mosekilde L, Rejnmark L. PTH(1–84) replacement therapy in hypoparathyroidism: a randomized controlled trial on pharmacokinetic and dynamic effects after 6 months of treatment. J Bone Miner Res. 2013;28(10):2232–43. https://doi.org/10.1002/JBMR.1964.

Article  CAS  PubMed  Google Scholar 

Mitchell DM, et al. Long-term follow-up of patients with hypoparathyroidism. J Clin Endocrinol Metab. 2012;97(12):4507–14. https://doi.org/10.1210/JC.2012-1808.

Article  CAS  PubMed  PubMed Central  Google Scholar 

“(Abstract MO0173). 33rd Annual Meeting of the American Society of Bone and Mineral Research. Vol 26(Suppl 1). San Diego, CA: J Bone Miner Res. 2011”

Clarke BL, Vokes TJ, Bilezikian JP, Shoback DM, Lagast H, Mannstadt M. Effects of parathyroid hormone rhPTH(1–84) on phosphate homeostasis and vitamin D metabolism in hypoparathyroidism: REPLACE phase 3 study. Endocrine. 2017;55(1):273–82. https://doi.org/10.1007/S12020-016-1141-0.

Article  CAS  PubMed  Google Scholar 

Mannstadt M, et al. Safety and efficacy of 5 years of treatment With recombinant human parathyroid hormone in adults with hypoparathyroidism. J Clin Endocrinol Metab. 2019;104(11):5136–47. https://doi.org/10.1210/JC.2019-01010.

Article  PubMed  PubMed Central  Google Scholar 

Tay YKD, et al. Therapy of hypoparathyroidism with rhpth(1–84): a prospective, 8-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2019;104(11):5601–10. https://doi.org/10.1210/JC.2019-00893.

Article  PubMed  PubMed Central  Google Scholar 

Sikjaer T, Rejnmark L, Rolighed L, Heickendorff L, Mosekilde L. The effect of adding PTH(1–84) to conventional treatment of hypoparathyroidism: a randomized, placebo-controlled study. J Bone Miner Res. 2011;26(10):2358–70. https://doi.org/10.1002/JBMR.470.

Article  CAS  PubMed  Google Scholar 

Cusano NE, et al. The effect of PTH(1–84) on quality of life in hypoparathyroidism. J Clin Endocrinol Metab. 2013;98(6):2356–61. https://doi.org/10.1210/JC.2013-1239.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tabacco G, et al. Quality of life in hypoparathyroidism improves with rhPTH(1–84) throughout 8 years of therapy. J Clin Endocrinol Metab. 2019;104(7):2748–56. https://doi.org/10.1210/JC.2018-02430.

Article  PubMed  PubMed Central  Google Scholar 

Cusano NE, et al. PTH(1–84) is associated with improved quality of life in hypoparathyroidism through 5 years of therapy. J Clin Endocrinol Metab. 2014;99(10):3694–9. https://doi.org/10.1210/JC.2014-2267.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Sikjaer T, Rolighed L, Hess A, Fuglsang-Frederiksen A, Mosekilde L, Rejnmark L. Effects of PTH(1–84) therapy on muscle function and quality of life in hypoparathyroidism: results from a randomized controlled trial. Osteoporos Int. 2014;25(6):1717–26. https://doi.org/10.1007/S00198-014-2677-6.

Article  CAS  PubMed  Google Scholar 

Vokes TJ, et al. Recombinant human parathyroid hormone effect on health-related quality of life in adults with chronic hypoparathyroidism. J Clin Endocrinol Metab. 2018;103(2):722–31. https://doi.org/10.1210/JC.2017-01471.

Article  PubMed  Google Scholar 

Tay YKD, Tabacco G, Bilezikian JP. Bone quality in hypoparathyroidism. Minerva Endocrinol. 2021;46(3):325–34. https://doi.org/10.23736/S2724-6507.21.03527-2.

Article  Google Scholar 

Cusano NE, et al. Therapy of hypoparathyroidism with PTH(1–84): a prospective four-year investigation of efficacy and safety. J Clin Endocrinol Metab. 2013;98(1):137–44. https://doi.org/10.1210/JC.2012-2984.

Article  CAS  PubMed  Google Scholar 

Rubin MR, et al. Therapy of hypoparathyroidism With PTH(1–84): a prospective six year investigation of efficacy and safety. J Clin Endocrinol Metab. 2016;101(7):2742–50. https://doi.org/10.1210/JC.2015-4135.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Rubin MR, et al. The effects of long-term administration of rhPTH(1–84) in hypoparathyroidism by bone histomorphometry. J Bone Miner Res. 2018;33(11):1931–9. https://doi.org/10.1002/JBMR.3543.

Article  CAS  PubMed  Google Scholar 

Cusano NE, et al. Changes in skeletal microstructure through four continuous years of rhPTH(1–84) therapy in hypoparathyroidism. J Bone Miner Res. 2020;35(7):1274–81. https://doi.org/10.1002/JBMR.4005.

Article  CAS  PubMed  Google Scholar 

Agarwal S, et al. The clinical and skeletal effects of long-term therapy of hypoparathyroidism with rhPTH(1–84). J Bone Miner Res. 2023;38(4):480–92. https://doi.org/10.1002/JBMR.4780.

Article  CAS  PubMed  Google Scholar 

Karpf DB, et al. A randomized double-blind placebo-controlled first-in-human phase 1 trial of transcon pth in healthy adults. J Bone Miner Res. 2020;35(8):1430–40. https://doi.org/10.1002/JBMR.4016.

Article  CAS  PubMed  Google Scholar 

Khan AA, et al. PaTH forward: a randomized, double-blind, placebo-controlled phase 2 trial of transcon pth in adult hypoparathyroidism. J Clin Endocrinol Metab. 2022;107(1):E372–85. https://doi.org/10.1210/CLINEM/DGAB577.

Article